Quizartinib Plus Chemotherapy Improves Survival vs Placebo in FLT3-ITD-Positive AML
Researchers sought to determine whether adding quizartinib to standard chemotherapy would improve survival in patients with newly diagnosed FLT3-ITD-positive AML.
Researchers sought to determine whether adding quizartinib to standard chemotherapy would improve survival in patients with newly diagnosed FLT3-ITD-positive AML.
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Researchers sought to determine whether reducing mitophagy would impact BH3 mimetic resistance in AML.
A literature review sought to identify nutritional challenges patients with acute myeloid leukemia and myelodysplastic syndrome experience.
Researchers sought to determine whether flow cytometry-based MRD at end of induction 2 would be a prognostic factor in pediatric KMT2A-rearranged AML.
Quizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations.
Researchers sought to determine whether IDH2 R172 mutations had an impact on survival in patients with myeloid neoplasms.
Researchers sought to determine whether venetoclax combined with idasanutlin would be safe and effective in patients with AML.
Researchers sought to determine the impact of TP53 mutations on infection and HCT rates in patients with MDS/AML.
Researchers sought to determine whether certain genetic variants would impact outcomes for patients with AML in first remission prior to undergoing allo-HSCT.